comprehensive -WSS

comprehensive

author：comprehensive 2025-09-06 03:55:38 - browse：5879

Vir Biotechnology said Thursday that a long-acting antibody drug designed to protect healthy individuals from influenza A failed to do so in a nearly 3,000-person clinical trial.

Volunteers who received the highest dose of the drug, known as VIR-2482, were only 16% less likely than the placebo group to develop symptomatic influenza A infections, as defined by trial criteria, over a seven-month period. The difference was not statistically significant.

The results are a setback in broader efforts to develop better protective measures against both seasonal and potential pandemic influenza strains. In the short term, Vir and outside experts hoped VIR-2482 could provide additional annual protection for at-risk groups like older adults, as flu vaccines are often only modestly effective.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Plastic surgeons increase patient psychiatric screenings

leisure time

WSS

In new study, freeze

Review: 'Barbie' will hit you like a shot in the heart

Marvel Studios reveals new trailer for 'The Marvels': Watch here

U.K. not yet recommending Vertex's CRISPR therapy for sickle cell

How artificial intelligence is being used to detect, treat cancer

Physicians and social media: If you see something, say something?

hotspot

comprehensive

leisure time

Alkermes shareholders re

Argenx readies a blockbuster opportunity with drug for autoimmune disease

Hepatitis C has a cure — but many Americans still lack access to it

Providers still hesitate to prescribe buprenorphine, study finds

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

A double vaccine crisis is endangering millions of children

23andMe had bad news about my health. I wish a person had delivered it

AbbVie dramatically boosts its spending on lobbying

What does generative AI mean for health care? We asked experts

FDA official pushes for dedicated emerging pathogens team

leisure time

Review: 'Barbie' will hit you like a shot in the heart

Providers still hesitate to prescribe buprenorphine, study finds

Methadone treatment changes are coming. Do they go far enough?

Russian special forces kill a gunman who broke into a private house near Moscow

Leading voice in opioid treatment defends methadone clinic system

SCOTUS questions limit to govt efforts to fight misinformation

focus

leisure time

hotspot

hotspot